Skip to main content
Open Forum Infectious Diseases logoLink to Open Forum Infectious Diseases
. 2017 Oct 4;4(Suppl 1):S434. doi: 10.1093/ofid/ofx163.1096

Treatment of HIV and Use of HAART in HIV Infected Patients with Acute Septic Shock

Christopher Polk 1, Samuel Webb 2, Nigel Rozario 3, Charity Moore 3, Michael Leonard 1
PMCID: PMC5630708

Abstract

Background

For HIV patients admitted with sepsis, ARVs are often stopped or held due to myriad concerns including drug interactions, acute renal failure, gastrointestinal dysfunction, or inability to administer crushed medications down feeding tubes. We seek to examine prescription patterns of HAART for HIV positive patients admitted for sepsis in our healthcare system and the impact of HAART prescription on patient outcomes.

Methods

We identified HIV positive patients from an institutional database of patients admitted for sepsis within our multi-hospital healthcare system and retrospectively extracted further clinical patient and laboratory information as well as information on HAART prescription by chart review. The impact of HAART prescription and immunologic and virologic parameters of HIV infection on mortality was examined.

Results

Inpatient mortality was 35% in HIV patients admitted for sepsis, compared with 17% for all patients with sepsis in our healthcare system. Opportunistic infections were identified in only 25% of patients while 56% had other infections identified. Only 55% of patients had HAART prescribed while inpatient. CD4 count, virologic suppression, APACHE score, presence of an opportunistic infection, admission to a tertiary care hospital, and inpatient prescription of HAART were all predictors of survival.

Table:

Factors impacting mortality in HIV patients with sepsis in univariate analysis.

Survivors (n = 50) Deaths (n = 28) Odds ratio of survival (p value)
Mean baseline CD4 count 309 64 (P < 0.01)
Virologic suppression (VL<200) 48% (n = 21 of 44) 22% (n = 5 of 23) 3.3 (P < 0.05)
Mean APACHE score 67 (n = 32) 110 (n = 17) (P < 0.01)
Opportunistic infection 18% (n = 9) 39% (n = 11) 0.34 (P < 0.05)
Tertiary hospital admission 50% (n = 25) 21% (n = 6) 3.7 (P < 0.05)
Inpatient HAART prescription 68% (n = 34) 32% (n = 9) 4.5 (P < 0.01)

In a multivariable analysis both CD4 count and inpatient HAART prescription predicted survival in our cohort with an odds ratio of survival of 3.3 for patients prescribed HAART inpatient compared with their untreated peers.

Conclusion

Immunologic and virologic status at time of admission predicted survival in HIV patients admitted for sepsis but prescription of HAART to HIV patients admitted for sepsis may increase survival.

Disclosures

C. Polk, Gilead Sciences: Investigator, Research support; Viiv Healthcare: Investigator, Research support


Articles from Open Forum Infectious Diseases are provided here courtesy of Oxford University Press

RESOURCES